| P50 | author | Kara L. Britt | Q37370390 |
| | John T. Price | Q39186637 |
| | Benjamin J Lang | Q61089823 |
| P2093 | author name string | Chau H Nguyen | |
| | Jessica L Vieusseux | |
| | Ryan C Chai | |
| | Michelle M Kouspou | |
| P2860 | cites work | HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor | Q24303612 |
| | Modulation of Akt kinase activity by binding to Hsp90 | Q24648565 |
| | Negative and positive regulation of gene expression by mouse histone deacetylase 1 | Q24672508 |
| | Heat shock protein 90 targeting therapy: state of the art and future perspective | Q26776302 |
| | Maximizing the Therapeutic Potential of HSP90 Inhibitors | Q26798318 |
| | Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers | Q27022514 |
| | Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues | Q27644429 |
| | 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer | Q27649087 |
| | Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90 | Q28143497 |
| | Systematic variation in gene expression patterns in human cancer cell lines | Q28145747 |
| | NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis | Q28276567 |
| | Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion | Q28284160 |
| | Targeting the dynamic HSP90 complex in cancer | Q28288602 |
| | New colorimetric cytotoxicity assay for anticancer-drug screening | Q29615418 |
| | HSP90 and the chaperoning of cancer | Q29617504 |
| | Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors | Q33621243 |
| | Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. | Q33848888 |
| | A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer | Q34898930 |
| | Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective | Q35551871 |
| | P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement | Q35720969 |
| | An acetylation site in the middle domain of Hsp90 regulates chaperone function | Q35729439 |
| | Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation | Q36217180 |
| | Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies. | Q36472987 |
| | TAp73 protein stability is controlled by histone deacetylase 1 via regulation of Hsp90 chaperone function | Q36685194 |
| | Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. | Q36938818 |
| | Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. | Q37068863 |
| | Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery | Q37070115 |
| | Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells | Q37120694 |
| | P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response | Q37226339 |
| | Physical and functional HAT/HDAC interplay regulates protein acetylation balance | Q37820140 |
| | Inhibiting HSP90 to treat cancer: a strategy in evolution | Q38026904 |
| | Drugging the HDAC6-HSP90 interplay in malignant cells. | Q38252444 |
| | Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions | Q38722650 |
| | Targeting HSF1 sensitizes cancer cells to HSP90 inhibition | Q39161041 |
| | MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? | Q39834203 |
| | Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin | Q40012118 |
| | Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism | Q40207997 |
| | MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research | Q40227151 |
| | Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin | Q40345142 |
| | Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs | Q40386853 |
| | The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line | Q40414429 |
| | Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. | Q40498632 |
| | Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line | Q40554428 |
| | ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin | Q40711250 |
| | Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. | Q41881419 |
| | HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells | Q46509566 |
| | Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin | Q46803761 |
| | A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma | Q48474924 |
| | A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). | Q51629344 |
| | Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? | Q73337742 |
| P433 | issue | 5 | |
| P304 | page(s) | 567-583 | |
| P577 | publication date | 2017-03-17 | |
| P1433 | published in | Molecular Oncology | Q2190736 |
| P1476 | title | Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors | |
| P478 | volume | 11 | |